German researchers have recently tested cannabidiol, or CBD, in conjunction with, traditional medications to study its effect on patients with schizophrenia. CBD oil has been shown to elevate anandamide levels in cerebrospinal fluid. Anandamide has been referred to as the “bliss molecule” due to the heightened sense of happiness it causes.
The study consisted of 88 schizophrenic patients, who were randomly given either 1,000mg of CBD or a placebo daily. At the conclusion of the trial, the CBD treatment group “had lower levels of positive psychotic symptoms and were more likely to have been rated as improved and as not severely unwell by the treating clinician.” Researchers recognized that the patients consuming CBD had increased anandamide levels, which correlated to a decrease in psychotic symptoms.